Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2

Molecular Cell

Volumn 4, Issue 1, 1999, Pages 1-10

  Lee, Hyunsook ^a,b   Trainer, Alison H ^b   Friedman, Lori S ^b   Thistlethwaite, Fiona C ^c   Evans, Martin J ^c   Ponder, Bruce A J ^b   Venkitaraman, Ashok R ^a,b  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GENETICS; CELL TRANSFORMATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; GENE MUTATION; MALIGNANT TRANSFORMATION; MITOSIS; MOLECULAR CLONING; NONHUMAN;

ANIMALIA; MURINAE;

EID: 0033166981     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80182-3     Document Type: Article

References (50)

1. Baumann, P., Benson, F.E., and West, S.C. (1997). Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87, 757-766.
2. Bertwistle, D., Swift, S., Marston, N.J., Jackson, L.E., Crossland, S., Crompton, M.R., Marshall, C.J., and Ashworth, A. (1997). Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res. 57, 5485-5488.
3. Brachmann, R.K., Vidal, M., and Boeke, J.D. (1996). Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl. Acad. Sci. USA 93, 4091-4095.
4. Brugarolas, J., and Jacks, T. (1997). Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair [news]. Nat. Med. 3, 721-722.
5. Cahill, D.P., Lengauer, C., Yu, J., Riggins, G.J., Willson, J.K.V., Markowitz, S.D., Kinzler, K.W., and Vogelstein, B. (1998). Mutations of mitotic checkpoint genes in human cancers. Nature 392, 300-303.
6. Campbell, M.S., and Gorbsky, G.J. (1995). Microinjection of mitotic cells with the 3F3/2 anti-phosphoepitope antibody delays the onset of anaphase. J. Cell Biol. 129, 1195-1204.
7. Chene, P. (1998). In vitro analysis of the dominant negative effect of p53 mutants. J. Mol. Biol. 281, 205-209.
8. Cho, Y., Gorina, S., Jeffrey, P.D., and Pavletich, N.P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355.
9. Collins, N., McManus, R., Wooster, R., Mangion, J., Seal, S., Lakhani, S., Ormiston, W., and Daly, P.A. (1995). Consistent loss of the wild-type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10, 1673-1675.
10. Connor, F., Bertwistle, D., Mee, P.J., Ross, G.M., Swift, S., Grigorieva, E., Tybulewicz, V.L., and Ashworth, A. (1997). Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat. Genet. 17, 423-430.
11. Corcoran, A.E., Smart, F.M., Cowling, R.J., Crompton, T., Owen, M., and Venkitaraman, A.R. (1996). The interleukin-7 receptor a chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. EMBO J. 15, 1924-1932.
12. Cross, S.M., Sanchez, C., Morgan, C., Schimke, M., Ramel, S., Idzerda, R.L., Raskind, W.H., and Reid, B.J. (1995). A p53 dependent mouse spindle checkpoint. Science 267, 1353-1356.
13. Daum, J.R., and Gorbsky, G.J. (1998). Casein kinase II catalyzes a mitotic phosphorylation on threonine 1342 of human DNA topoisomerase llalpha, which is recognized by the 3F3/2 phosphoepitope antibody. J. Biol. Chem. 273, 30622-30629.
14. Davenport, J.W., Fernandes, E.R., Harris, L.D., Neale, G.A., and Goorha, R. (1999). The mouse mitotic checkpoint gene bub1b, a novel bub1 family member, is expressed in a cell cycle-dependent manner. Genomics 55, 113-117.
15. Farr, K.A., and Hoyt, M.A. (1998). Bub1p kinase activates the Saccharomyces cerevisiae spindle assembly checkpoint. Mol. Cell. Biol. 18, 2738-2747.
16. Friedman, L.S., Thistlethwaite, F.C., Patel, K.J., Yu, V.P., Lee, H., Venkitaraman, A.R., Abel, K.J., Carlton, M.B., Hunter, S.M., Colledge, W.H., Evans, M.J., and Ponder, B.A. (1998). Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 58, 1338-1343.
17. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G.F. (1996). Abnormal centrosome amplification in the absence of p53. Science 271, 1744-1747.
18. Glebov, O.K., McKenzie, K.E., White, C.A., and Sukumar, S. (1994). Frequent p53 gene mutations and novel alleles in breast cancer. Cancer Res. 54, 3703-3709.
19. Gorbsky, G.J., and Ricketts, W.A. (1993). Differential expression of a phosphoepitope at the kinetochores of moving chromosomes. J. Cell Biol. 122, 1311-1321.
20. Gretarsdottir, S., Thorlacius, S., Valgardsdottir, R., Gudlaugsdottir, S., Sigurdsson, S., Steinarsdottir, M., Jonasson, J.G., Anamthawat-Jonsson, K., and Eyfjord, J.E. (1998). BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res. 58, 859-862.
21. Grutz, G.G., Bucher, K., Lavenir, I., Larson, T., Larson, R., and RabBitts, T.H. (1998). The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J. 17, 4594-4605.
22. Gualberto, A., Aldape, K., Kozakiewicz, K., and Tlsty, T.D. (1998). An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrputs spindle checkpoint control. Proc. Natl. Acad. Sci. USA 95, 5166-5171.
23. Gudmundsson, J., Johannesdottir, G., Bergthorsson, J., Arason, A., Ingvarsson, S., Egilsson, V., and Barkardottir, R. (1995). Different tumour types from BRCA2 carriers show wild-type chromosome deletions on 13q12q13. Cancer Res. 55, 4830-4832.
24. Hardwick, K.G., Weiss, E., Luca, F.C., Winey, M., and Murray, A.W. (1996). Activation of the budding yeast spindle assembly checkpoint without mitotic spindle disruption. Science 273, 953-956.
25. Hoyt, M.A., Totis, L., and Roberts, B.T. (1991). S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell 66, 507-517.
26. Jonkers, J., Korswagen, H.C., Acton, D., Breuer, M., and Berns, A. (1997). Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. EMBO J. 16, 441-450.
27. Lanni, J.S., and Jacks, T. (1998). Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18, 1055-1064.
28. Lee, H., Lee, Y.-H., Huh, Y.-S., Moon, H.M., and Yun, Y. (1995). X-gene product antagonizes the p53-mediated inhibition of Hepatitis B virus replication through down-regulation of Pregenomic/Core promoter. J. Biol. Chem. 270, 31405-31412.
29. Li, R., and Murray, A.W. (1991). Feedback control of mitosis in budding yeast. Cell 66, 519-531.
30. Ludwig, T., Chapman, D.L., Papaioannou, V.E., and Efstratiadis, A. (1997). Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226-1241.
31. Marmorstein, L.Y., Ouchi, T., and Aaronson, S.A. (1998). The BRCA2 gene product functionally interacts with p53 and RAD51. Proc. Natl. Acad. Sci. USA 95, 13869-13874.
32. Milner, J., and Medcalf, E.A. (1991). Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765-774.
33. Milner, J., Medcalf, E., and Cook, C.A. (1991). Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol. 11, 12-19.
34. Minn, A.J., Boise, L.H., and Thompson, C.B. (1996). Expression of Bcl-xl and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10, 2621-2631.
35. Nicklas, R.B., Ward, S.C., and Gorbsky, G.J. (1995). Kinetochore chemistry is sensitive to tension and may link mitotic forces to a cell cycle checkpoint. J. Cell Biol. 130, 929-939.
36. Patel, K.J., Yu, V.P., Lee, H., Corcoran, A., Thistlethwaite, F.C., Evans, M.J., Colledge, W.H., Friedman, L.S., Ponder, B.A., and VenkiTaraman, A.R. (1998). Involvement of Brca2 in DNA repair. Mol. Cell 1, 347-357.
37. Rhei, E., Bogomolniy, F., Federici, M.G., Maresco, D.L., Offit, K., Robson, M.E., Saigo, P.E., and Boyd, J. (1998). Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res. 58, 3193-3196.
38. Rudner, A.D., and Murray, A.W. (1996). The spindle assembly checkpoint. Curr. Opin. Cell Biol. 8, 773-780.
39. Savage, J.R.K. (1975). Classification and relationships of induced chromosomal structural changes. J. Med. Genet. 12, 103-122.
40. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
41. Sharan, S.K., Morimatsu, M., Albrecht, U., Lim, D., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804-810.
42. Shinohara, A., Ogawa, H., and Ogawa, T. (1992). Rad51 protein involved in repair and recombination in S. cerevesiae is a RecA-like protein. Cell 69, 457-470.
43. Suzuki, A., de la Pompa, J.L., Hakem, R., Elia, A., Yoshida, R., Mo, R., Nishina, H., Chuang, T., Wakeham, A., Itie, A., et al. (1997). Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. 11, 1242-1252.
44. Tavtigian, S.V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., et al. (1996). The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds [see comments]. Nat. Genet. 12, 333-337.
45. Taylor, S.S., and McKeon, F. (1997). Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 89, 727-735.
46. Taylor, S.S., Ha, E., and McKeon, F. (1998). The human homologue of bub3 is required for kinetochore localization of Bub1 and a Mad3/ Bub1-related protein kinase. J. Cell Biol. 142, 1-11.
47. Unger, T., Nau, M.M., Segal, S., and Minna, J.D. (1992). p53: A trans-dominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11, 1383-1390.
48. Waters, J.C., Chen, R.H., Murray, A.W., and Salmon, E.D. (1998). Localization of Mad2 to kinetochores depends on microtubule attachment, not tension. J. Cell Biol. 141, 1181-1191.
49. Wong, A.K.C., Pero, R., Ormonde, P.A., Tavtigian, S.V., and Bartel, P.L. (1997). RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J. Biol. Chem. 272, 31941-31944.
50. Wooster, R., Bignell, J., Lancaster, S., Swift, S., Seal, S., Mangion, N., Collins, S., Gregory, C., Gumbs, G., and Micklem, R. (1995). Identification of the breast-cancer susceptibility gene BRCA2. Nature 378, 789-792.